Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment-na ve HIV-1-infected patients

被引：5
|
作者：
Zolopa, A. [1 ]
Gallant, J. [2 ]
Cohen, C. [3 ]
Sax, P. [4 ]
Dejesus, E. [5 ]
Mills, A. [6 ]
Wohl, D. [7 ]
Liu, H. [8 ]
Rhee, M. [8 ]
Szwarcberg, J. [8 ]
机构：
[1] Stanford Univ, Palo Alto, CA 94304 USA
[2] Johns Hopkins Sch Med, Baltimore, MD USA
[3] Community Res Initiat New England, Boston, MA USA
[4] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA
[5] Orlando Immunol Ctr, Orlando, FL USA
[6] Anthony Mills MD Inc, Los Angeles, CA USA
[7] Univ N Carolina, Chapel Hill, NC USA
[8] Gilead Sci, Foster City, CA USA
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2012年 / 15卷
关键词：
D O I：
10.7448/IAS.15.6.18219
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：23 / 23
页数：1
相关论文
共 50 条
  • [1] Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF at week 96 in treatment-na ve HIV-1-infected patients
    Rockstroh, J.
    DeJesus, E.
    Henry, K.
    Molina, J.
    Gathe, J.
    Wei, X.
    Fordyce, X.
    Rhee, M.
    Szwarcberg, J.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 23 - 23
  • [2] Week 96 efficacy and safety data: Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF in treatment-naive HIV-1-infected patients
    Orkin, C.
    Rockstroh, J.
    DeJesus, E.
    Henry, K.
    Molina, J.
    Gathe, J.
    Wei, X.
    Fordyce, M.
    Rhee, M.
    Smith, A.
    Szwarcberg, J.
    [J]. HIV MEDICINE, 2013, 14 : 56 - 56
  • [3] Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has non-inferior efficacy and favorable safety compared to efavirenz/emtricitabine/tenofovir DF in treatment naive HIV-1 infected subjects
    Sax, P.
    DeJesus, E.
    Mills, A.
    Zolopa, A.
    Cohen, C.
    Wohl, D.
    Gallant, J.
    Bosse, M.
    White, K.
    Liu, C.
    Plummer, A.
    Kearney, B.
    Quirk, E.
    Cheng, A.
    [J]. HIV MEDICINE, 2012, 13 : 9 - 9
  • [4] Week 144 efficacy and safety data: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (Stribild) demonstrates durable efficacy and differentiated safety compared to Atazanavir boosted by Ritonavir plus Emtricitabine/Tenofovir DF at week 144 in treatment-naive HIV-1-infected patients
    Orkin, C.
    Clumeck, N.
    Girard, P-M
    Henry, K.
    Gathe, J.
    Rockstroh, J.
    DeJesus, E.
    Yau, S.
    Smith, A.
    Wei, X.
    White, K.
    Fordyce, M.
    Rhee, M.
    Szwarcberg, J.
    [J]. HIV MEDICINE, 2014, 15 : 114 - 114
  • [5] Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients
    White, Kirsten L.
    Kulkarni, Rima
    McColl, Damian J.
    Rhee, Martin S.
    Szwarcberg, Javier
    Cheng, Andrew K.
    Miller, Michael D.
    [J]. ANTIVIRAL THERAPY, 2015, 20 (03) : 317 - 327
  • [6] Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV patients with renal impairment
    Post, F.
    Andrade-Villanueva, J.
    Fisher, M.
    Winston, J.
    Liu, Y.
    Zhong, L.
    Cheng, A.
    Rhee, M.
    Szwarcberg, J.
    [J]. HIV MEDICINE, 2014, 15 : 115 - 115
  • [7] 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects
    Porter, Danielle P.
    Kulkarni, Rima
    Fralich, Todd
    Miller, Michael D.
    White, Kirsten L.
    [J]. HIV CLINICAL TRIALS, 2015, 16 (01): : 30 - 38
  • [8] Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Atazanavir plus Ritonavir plus Emtricitabine/Tenofovir DF in Antiretroviral-Naive Patients
    Kulkarni, Rima
    Abram, Michael E.
    McColl, Damian J.
    Barnes, Tiffany
    Fordyce, Marshall W.
    Szwarcberg, Javier
    Cheng, Andrew K.
    Miller, Michael D.
    White, Kirsten L.
    [J]. HIV CLINICAL TRIALS, 2014, 15 (05): : 218 - 229
  • [9] Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF in HIV-Infected Patients With Mild-to-Moderate Renal Impairment
    Post, Frank A.
    Winston, Jonathan
    Andrade-Villanueva, Jaime F.
    Fisher, Martin
    Liu, YaPei
    Beraud, Christophe
    Abram, Michael E.
    Graham, Hiba
    Rhee, Martin S.
    Cheng, Andrew K.
    Szwarcberg, Javier
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2015, 68 (03) : 310 - 313
  • [10] Reports of viral hepatitis B and C in HIV patients participating in clinical trials of elvitegravir/cobicistat/tenofovir DF/emtricitabine and cobicistat-boosted atazanavir plus tenofovir DF/emtricitabine
    Quirk, E.
    Graham, H.
    Liu, C.
    Rhee, M.
    Piontkowsky, D.
    Szwarcberg, J.
    [J]. ANTIVIRAL THERAPY, 2013, 18 : A63 - A63
12345